There was concern that oseltamivir resistance would spread widely through communities, but that didn't prove to be the case. All documented cases have occurred in patients on oseltamivir or in close contacts of patients treated with the drug, according to Dr. Weinberg.
Dr. Weinberg disclosed serving as a consultant to MedImmune, Astellas, GlaxoSmithKline, and Merck.
Laninamivir is in phase III trials and is showing a favorable safety profile against oseltamivir resistance.
Source Dr. weinberg